As filed with the Securities and Exchange Commission on January 23, 2026. Registration Statement No. 333-292131 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________ AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________ Invea Therapeutics, Inc. (Exact name of registrant as specified in its charter) __________________________________ Delaware 2834 87-3198325 (State or other jurisdiction of in ...

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and com ...

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in ...

RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders’ equity ...

RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders’ equity ...

Investors with a lot of money to spend have taken a bearish stance on Liquidia (NASDAQ:LQDA).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LQDA, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted ...

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 AIM ImmunoTech Inc. (I.R.S. Employer Identification Number) 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Oc ...

1月23日，国家知识产权局副局长芮文彪在国新办新闻发布会上表示，截至2025年底，长三角地区、京 津冀地区和广东省的发明专利有效量分别为173.4万件、91.6万件和89.9万件，合计约占国内总量的 2/3；有效注册商标量合计2805.8万件，占国内总量一半以上。 上述数据不仅在国内区域经济中表现优异，放眼全球也引人瞩目。发明专利有效量是反映科技创新实力 的重要指标，一个地方积累了足够多的发明专利，那些看得见的技术创新，在很大程度上会决定当地经 济的科技含量。芮文彪介绍，在世界知识产权组织发布的2025年全球百强创新集群排名中，深圳-香港- 广州、北京、上海-苏州集群分别位居全球第1、第4和第6。这些区域充分发挥了创新高地的作用，成为 我国迈向知识产权强国的战略支点。 粤港澳大湾区在科技创新方面的突出表现，对此观察的角度有很多。 就发明专利而言，总量很重要，但质量更重要。而粤港澳大湾区在专利质量方面的表现同样优异，2025 年，国家知识产权局发布第25届中国专利奖授奖决定，结果显示，深圳创新主体再获佳绩，总获奖数量 81项，约占全国奖项总数的10.5%，创下历史新高。其中，获得金奖项目9个，含中国专利金奖5项 ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

San Diego, California--(Newsfile Corp. - January 23, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of interim data from its Phase 2 (EU) clinical study of TTI-0102 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) at Mitocon 2026 - a leadi ...